Skip to main content

Find Clinical Trials

Home
Conditions
Recurrent Prostate Cancer

Clinical trial condition

Recurrent Prostate Cancer

Explore clinical trials studying Recurrent Prostate Cancer. Study availability and eligibility vary by location and protocol.

87 public trials 9 recruiting studies

Refine in advanced search Browse all conditions

Recurrent Prostate Cancer trial results

Completed

Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer

NCT00103194

Conditions: Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +12 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Completed

Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer

NCT00956163

Conditions: Bone Metastases, Genital Diseases, Genital Diseases, Male, +14 more
Locations: Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States

View Trial Details

Completed

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00337077

Conditions: Adenocarcinoma of the Prostate, Genital Diseases, Genital Diseases, Male, +11 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Community Hospital of Monterey Peninsula Monterey, California, United States

Manchester Memorial Hospital Manchester, Connecticut, United States

Boca Raton Regional Hospital Boca Raton, Florida, United States

View all 147 locations

View Trial Details

Completed

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00058253

Conditions: Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +10 more
Locations: Memorial Sloan-Kettering Cancer Center New York, United States

View Trial Details

Completed

Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer

NCT00330161

Conditions: Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +9 more
Locations: University of Michigan Ann Arbor, Michigan, United States

View Trial Details

Completed

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00110214

Conditions: Adenocarcinoma of the Prostate, Genital Diseases, Genital Diseases, Male, +11 more
Locations: Yale University New Haven, Connecticut, United States

Cancer and Leukemia Group B Chicago, Illinois, United States

View Trial Details

Completed

Ixabepilone in Treating Patients With Metastatic Prostate Cancer

NCT00087139

Conditions: Adenocarcinoma of the Prostate, Genital Diseases, Genital Diseases, Male, +10 more
Locations: The Medical Center of Aurora Aurora, Colorado, United States

Boulder Community Hospital Boulder, Colorado, United States

Penrose-Saint Francis Healthcare Colorado Springs, Colorado, United States

Porter Adventist Hospital Denver, Colorado, United States

View all 162 locations

View Trial Details

Completed

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

NCT01338792

Conditions: Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +9 more
Locations: USC/Norris Comprehensive Cancer Center Los Angeles, California, United States

View Trial Details

Completed

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

NCT00031681

Conditions: Adenocarcinoma, Adnexal Diseases, Advanced Adult Primary Liver Cancer, +182 more
Locations: University of Virginia Charlottesville, Virginia, United States

View Trial Details

Completed

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

NCT00016107

Conditions: Adenocarcinoma of the Prostate, Genital Diseases, Genital Diseases, Male, +11 more
Locations: Cancer and Leukemia Group B Chicago, Illinois, United States

View Trial Details